Navigation Links
Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
Date:9/3/2007

osts decreased in the current year period, due to notes being converted in the corresponding prior year period. The basic and diluted loss per share was $0.01 on approximately 108 million weighted average common shares outstanding for the three months ended June 30, 2007 and 2006, respectively.

Total revenues of $889,000 for the six months ended June 30, 2007, decreased 23% compared to revenues of $1,149,000 in the corresponding prior year period. The Company's net loss applicable to common stockholders for the six months ended June 30, 2007 and 2006 was $1,650,000 and $1,736,000, respectively. The operating loss for the six month period ended June 30, 2007, before interest expense and amortization of the loan discount, warrants and prepaid financing cost, was $1,146,000 compared to $1,310,000 in the prior year period. Non-cash loan amortization expense for the six months ended June 30, 2007 was $390,000 compared to $405,000 in the corresponding prior year period. This decrease is attributable to the conversion of notes in the prior year period. The basic and diluted loss per share was $0.02 on approximately 108 million weighted average common shares outstanding for the six months ended June 30, 2007 as compared to a basic and diluted loss of $0.02 per share on approximately 107 million weighted average common shares outstanding for the corresponding prior year period.

"Progress with targeted accounts in the second quarter supports our belief that we will close sufficient orders during the second half of the year necessary to achieve profitability. Further, we believe our current sales activity indicates that we now have the breadth of eSignature product offerings, derived from our experience with large scale deployments with credible top-tier financial enterprises, required to sell effectively to both end-users and channel partners thereby providing CIC competitive differentiation and the foundation necessary for sustained revenue growth and profitabili
'/>"/>

SOURCE Communication Intelligence Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology news :

1. Elephants imitate sounds as a form of social communication
2. Sequencing of marine bacterium will help study of cell communication
3. Scientists journey to southern Africa to unravel the secret world of elephant communication
4. Underground tunnels discovered as means for communication between immune system cells
5. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
6. High-resolution light microscope reveals the fundamental mechanisms of nerve communication
7. First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown
8. Immune cell communication key to hunting viruses, Jefferson immunologists show
9. Ape gestures offer clues to the evolution of human communication
10. Noise echoes in cell communications
11. Discovery of master switch for the communication process between chloroplast and nuclei of plants
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2IGC scientist receives prestigious EMBO installation grant 2Orphanage Receives Nearly 241 Million from Private Donor 53804 1Orphanage Receives Nearly 241 Million from Private Donor 53804 2Orphanage Receives Nearly 241 Million from Private Donor 53804 3SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 1SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 2SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 1Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 2Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 4Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 5Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 6Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 7